EP
CPRX

Essential Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Essential Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16K Buy
37
+12
+48% +$354 ﹤0.01% 2176
2026
Q1 		$619 Buy
25
+2
+9% +$48 ﹤0.01% 2372
2025
Q4 		$537 Buy
23
+7
+44% +$156 ﹤0.01% 2216
2025
Q3 		$315 Sell
16
-487
-97% -$10K ﹤0.01% 2311
2025
Q2 		$10.9K Buy
+503
New +$11.9K ﹤0.01% 822

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Essential Partners's CPRX Position: Q2 2026 in Review

Essential Partners increased its Catalyst Pharmaceutical (CPRX) stake by 48% in Q2 2026, buying an estimated $354 and bringing the position to 37 shares worth $1.16K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

Essential Partners first reported a position in CPRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.9K in Q2 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Essential Partners held 37 shares of Catalyst Pharmaceutical worth $1.16K as of Q2 2026.
  • Essential Partners bought 12 Catalyst Pharmaceutical shares in Q2 2026, an estimated $354.
  • Catalyst Pharmaceutical made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2176 holding.
  • Essential Partners first reported a position in Catalyst Pharmaceutical in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Catalyst Pharmaceutical position peaked at $10.9K in Q2 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.